

Do you deserve the Patients you Get? – Creating Results Driven Practice!

Dr Ari Gronich

The Performance Therapist, United States.

Abstract

In patients with neurological injuries, acute treatment of cerebral edoema and high intracranial pressure is a prevalent problem. There are few practical suggestions for selecting and monitoring therapies for the initial therapy of cerebral edoema for maximum efficacy and safety. In the acute treatment of cerebral edoema, this guideline assesses the usefulness of hyperosmolar drugs (mannitol, HTS), corticosteroids, and certain non-pharmacologic interventions. Clinicians must be able to choose appropriate medications for the first management of cerebral edoema based on the current information while balancing efficacy and safety. Methodologies: The Neurocritical Care Society recruited experts in neurocri. Using the PICO model, the group came up with 16 clinical questions about the early therapy of cerebral edoema in distinct neurological lesions. Through July 2018, a research librarian conducted a comprehensive literature search. The panel reviewed the identified articles for inclusion in each PICO question and abstracted the necessary data for relevant publications.

Biography:

Ari Gronich is known as “The Performance Therapist” and the go to guy for Sports and Accident Injury Rehabilitation and Prevention. He is the founder and CEO of Achieve Health USA LLC, founder and innovator of the Performance Therapy Academy Master Education System, Host of the

Create a New Tomorrow Podcast, and on the advisory board of several health and wellness nonprofit organizations. Ari has been highly trained in many disciplines within the fields of bodywork, kinesiology, nutrition, health, and sports therapy. He has over 25,000 hours of hands on work and 5000 plus hours of training and internship as well as has trained hundreds of other therapists in the field.

Citation : Dr Ari Gronich, Do you deserve the Patients you Get? – Creating Results Driven Practice!, International Conference on Alzheimer’s and Parkinson’s disease.